# Sunna

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sunna

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.sunnatech.com
- Total disclosed funding: $3M
- Latest round: Series A (Nov 14, 2017)
- Investors on record: 1

## About

Established in 2015 and based in Shanghai, China, Sunna operates as a medical consumables developer that mainly provides artificial blood vessels and nano-functional fibre membrane materials. The founder and chairman of the company, Weiming Dai graduated from University of California, Berkeley. The company cooperates with hospitals and universities such as Huashan Hospital, Donghua University, and Shanghai Jiaotong University. In November 2024, Sunna closed pre-series A funding led by new investor FIRHealth Capital.

The company mainly provides medical consumables and nano-functional fibre membrane materials. Medical consumables include small-calibre artificial blood vessels, anti-haze masks, anti-haze window screens, and children's protective masks. Artificial blood vessels can be used in medical scenarios such as cardiovascular surgery or dialysis for kidney patients. Anti-haze window screens use the filtering properties of nanofibre membranes and are applied to window screen products, which are suitable for windows in various buildings such as homes, offices, and schools.

The company generates revenue by providing nano-functional fibre membrane materials and medical consumables such as artificial blood vessels, anti-haze masks, and anti-haze window screens.

The company will use the pre-series A funding for clinical experimental research application of small-calibre artificial blood vessel products, and to accelerate the clinical transformation of biological micro-nano material technology.

## Funding rounds

- Series A, Nov 14, 2017, $3M — Jiadaogu Capital

## Investors

- Jiadaogu Capital (https://capitalatlas.ai/funds/jiadaogu-capital) — Series A